Articles Tagged With: cardiovascular
-
Cardiovascular Risk with mRNA COVID Vaccines
A large, nationwide population study in Sweden of the risk of adverse cardiovascular events after messenger ribonucleic acid (mRNA) COVID-19 vaccinations has shown that, except for rare cases of myopericarditis, severe cardiovascular events, such as myocardial infarction, heart failure, and stroke, are reduced, probably because of the prevention of COVID infection.
-
From Glucocentricity to a Multi-Risk Strategy: An Updated Approach to Managing Chronic Kidney Disease
This article discusses an important microvascular complication of diabetes mellitus, chronic kidney disease (CKD), which affects more than one-third of patients with diabetes. There is substantial evidence that early diagnosis and management can delay or prevent the progression of CKD, making its prevention, diagnosis, and treatment a priority for the primary care clinician.
-
Modifiable Cardiovascular Risk Factors and Late-Life Brain Health
The major modifiable risk factors for cardiovascular diseases are delineated in Life’s Essential 8 (LE8), developed by the American Heart Association. These risk factors are blood pressure, glucose, cholesterol, body mass index, smoking, physical activity, diet, and sleep duration. The investigators in this analysis of two large databases in the United Kingdom and the United States, demonstrated that cardiovascular health, as defined by the LE8, will also predict brain health later in life.
-
Unique Ethical Concerns with AI-Enabled Cardiovascular Care
Multiple artificial intelligence (AI) -based cardiovascular devices are currently being developed and evaluated. In a recent study, researchers sought to identify specific barriers and facilitators to trustworthy and ethical use of AI in cardiovascular care.
-
Bempedoic Acid (Nexletol) and Bempedoic Acid and Ezetimibe (Nexlizet)
The U.S. Food and Drug Administration is expected to update the indications for bempedoic acid and bempedoic acid/ezetimibe. Esperion has submitted clinical evidence in the form of Cholesterol Lowering via Bempedoic Acid an ACL-inhibiting Regimen (CLEAR) that demonstrated that bempedoic acid was associated with a lower risk of major adverse cardiovascular events compared to placebo. Bempedoic acid and bempedoic acid/ezetimibe are distributed by Esperion as Nexletol and Nexlizet, respectively.
-
Long-Term Antiplatelet Therapy After PCI
The five-year follow-up of patients randomized to clopidogrel vs. aspirin monotherapy beyond one year after percutaneous coronary intervention has shown that clopidogrel is noninferior, but not superior, to aspirin for preventing the combined endpoint of adverse cardiovascular or major bleeding events.
-
Nitrates in Food Reduce Cardiovascular Risk
Dietary nitrates, such as in beetroot juice, improve the cardiovascular risk profile, lowering blood pressure and enhancing endothelial function.
-
How Many Steps a Day Will Improve Patients’ Longevity?
A systematic review and meta-analysis of studies of the association of step counts and cadence with all-cause mortality and cardiovascular events showed the benefits in these outcomes are statistically significant, at about 2,600 steps/day and peak at about 8,000 steps/day. Also, faster step cadence augments these benefits.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in People Living with HIV
A large randomized, controlled trial (REPRIEVE) conducted by Grinspoon and colleagues showed that in participants living with human immunodeficiency virus (HIV) who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin had a 35% lower risk of experiencing a major adverse cardiovascular event over a follow-up of approximately five years than those who received placebo.
-
Intensive Blood Pressure Control May Augment Cerebral Blood Flow
Patients with hypertension were randomized to intensive vs. standard blood pressure control and underwent baseline and follow-up cerebral perfusion imaging. Intensive blood pressure treatment was associated with improved cerebral perfusion over time.